Tempest Posts Q2 Loss, $0.8M Cash, and New CAR-T Collaboration
TPST sits 43% above its 52-week low of $0.84.
Summary
Tempest Therapeutics reported Q2 2026 results with a $5.2M net loss and only $0.8M in cash, while announcing a new CAR-T collaboration and positive interim data for TPST-2003.
Key Events · Earnings and Guidance · TPST
-
Q2 Loss and Cash Crunch
Net loss of $5.2M for Q2 2026; cash and cash equivalents fell to $0.8M from $7.7M at year-end 2025, with a stockholders' deficit of $1.1M.
-
New CAR-T Collaboration
Executed a development collaboration with Senlang Biotechnology for TPST-4003, a CD7-targeted in vivo CAR-T, with first patient dosing anticipated in Q4 2026.
-
Positive TPST-2003 Data
Reported 100% complete response rate among 15 CAR-T-naïve efficacy evaluable patients across REDEEM-1 and POEMS-1 trials.
-
Board Additions
Appointed Drake Richey and John Yee, MD, MPH, as independent directors.
Analysis · TPST · Life Sciences
A $5.2 million net loss for Q2 2026 left Tempest Therapeutics with just $0.8 million in cash and a stockholders' deficit of $1.1 million. To advance TPST-4003, an in vivo CAR-T candidate, the company announced a new collaboration with Senlang Biotechnology, with first patient dosing expected in Q4 2026. Positive interim data for TPST-2003 showed a 100% complete response rate in 15 CAR-T-naïve patients. The cash position is critically low, and the company continues to rely on warrant inducements and partnerships to fund operations.
At the time of this filing, TPST was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7M. The 52-week trading range was $0.84 to $12.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.